Medical Advocates
Indinavir (Crixivan)
 
Journal Citations:
Adult/Adolescent Indications

IND/EFV                   
IND/NFV                  
IND/RTV                      
IND/ZDV/3TC
 Misc Regimens
 Drug Comparison Studies



 
Journal Main Page Main New/Newsworthy  Home Page      
Last Update:  August 21, 2015
Documents identified with this icon  are in Portable Document Format (PDF) and require the  Adobe Acrobat Reader 6 .
Perinatal Journal Data are integrated with Perinatal Conference Data in the Perinatal Data Page.
Pediatric Journal Data are integrated with Pediatric  Conference Data in the Pediatric Data Page
Indinavir/Efavirenz Regimens
       
  Pharmacokinetics of Indinavir/Ritonavir (800/100 mg) in Combination With Efavirenz
(600 mg) in HIV-1-Infected Subjects.
 Boyd MA, Aarnoutse RE, Ruxrungtham K, et al 
J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):134-9.
 Abstract
 
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
 Saah AJ, Haas DW, DiNubile MJ, et al.
 J Infect Dis 2003 Apr 1;187(7):1157-62
 Abstract
 
Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency
Virus-Infected Subjects.
 DiCenzo R, Forrest A, Squires KE, et al
Antimicrob Agents Chemother 2003 Jun;47(6):1929-1935
 Abstract
Indinavir/Nelfinavir Regimens
       
 
Pharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir,
Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir: The MaxCmin1 and 2 Trials.
 Justesen US, Fox Z, Pedersen C, et al
Basic Clin Pharmacol Toxicol. 2007 Nov;101(5):339-44.
 Abstract

Plasma Levels of Indinavir and Nelfinavir at Time of Virologic Response May Have a
Different Impact on the Risk of Further Virologic Failure in HIV-Infected Patients.
 Le Moing V, Peytavin G, Journot V, et al 
J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-499.
 Abstract

Coadministration of Indinavir and Nelfinavir in Human Immunodeficiency Virus Type
1-Infected Adults: Safety, Pharmacokinetics, and Antiretroviral Activity.
 Riddler SA, Havlir D, Squires KE, et al.
Antimicrob Agents Chemother 2002 Dec;46(12):3877-3882
 Abstract
Indinavir/Ritonavir Regimens
       
 
Influence of Body Weight on Achieving Indinavir Concentrations Within Its Therapeutic
Window in HIV-Infected Thai Patients Receiving Indinavir Boosted With Ritonavir.
 Cressey TR, Urien S, Hirt D, et al
Ther Drug Monit. 2011 Feb;33(1):25-31.
 Abstract

Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in
HIV1-infected patients guided by therapeutic drug monitoring.
 Wasmuth JC, Rodermann E, Voigt E, et al
Eur J Med Res. 2007 Jul 26;12(7):289-94
Abstract
 
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with
combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
 Boyd MA, Siangphoe U, Ruxrungtham K, et al 
HIV Med. 2005 Nov;6(6):410-20
 Abstract
 
Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics,
efficacy and tolerabilit.
 Cressey TR, Leenasirimakul P, Jourdain G,  et al
J Antimicrob Chemother. 2005 May 9;
 Abstract
 
Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients:
comparison of 800/100 mg and 400/100 mg twice daily.
 Konopnicki D, De Wit S, Poll B, et al 
HIV Med. 2005 Jan;6(1):1-6.
 Abstract
 
Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals.
 Acosta EP, Wu H, Hammer SM, et al 
J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1358-1366.
 Abstract

The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals
 from an inner-city minority population: a pilot study.
 Jayaweera DT, Scerpella E, Robinson M  
 Int J STD AIDS. 2003 Nov;14(11):732-6.
 Abstract

A  randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir
 Teira R, Camara MM, Escobar A 
Med Clin (Barc). 2003 Nov 5;121(14):532-4.
 Abstract

Pharmacokinetics of Indinavir/Ritonavir (800/100 mg) in Combination With Efavirenz
(600 mg) in HIV-1-Infected Subjects.
 Boyd MA, Aarnoutse RE, Ruxrungtham K, et al 
J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):134-9.
 Abstract

Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior
protease inhibitor failures.
 Campo RE, Moreno JN, Suarez G, et al 
AIDS. 2003 Sep 5;17(13):1933-9.
 Abstract
 
Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human
Immunodeficiency Virus Type 1-Infected Patients: The MaxCmin1 Trial.
 Dragsted UB, Gerstoft J, Pedersen C, et al.  
 J Infect Dis. 2003 Sep 1;188(5):635-42.
 Abstract
 
Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics
and long-term clinical outcome follow-up.
 Justesen US, Levring AM, Thomsen A,  et al
HIV Med. 2003 Jul;4(3):250-254.
Abstract
 
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with
suppressed viral load.
 Arnaiz JA, Mallolas J, Podzamczer D,  et al
AIDS. 2003 Apr 11;17(6):831-40
Abstract
 
Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 200-mg Regimen in
HIV-Infected Adults Failing a Protease Inhibitor Regimen.
Katner HP, Paar DP, Nadler JP, et al.
Acquir Immune Defic Syndr 2002 Dec 15;31(5):483-7
 Abstract
 
Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in
Protease Inhibitor-Naive HIV-Infected Adults.
 Young B, Fischl MA, Wilson HM, et al.  
J Acquir Immune Defic Syndr 2002 Dec 15;31(5):478-82
 Abstract
 
Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based
Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia.
 Shulman N, Zolopa A, Havlir D, et al.
Antimicrob Agents Chemother 2002 Dec;46(12):3907-3916
 Abstract
 
Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse
transcriptase inhibitors in patients with hiv/aids who have failed multiple antiretroviral combinations.
Grodesky M, Acosta EP, Fujita N et al
HIV Clin Trials 2001 May-Jun;2(3):193-9
 Abstract
 
A Clinical Study of the Combination of 100 mg Ritonavir plus 800 mg Indinavir as Salvage
Therapy: Influence of Increased Plasma Drug Levels in the Rate of Response.
Casado JL, Moreno A, Sabido R
HIV Clin Trials 2000 Jul-Aug;1(1):13-9
 Abstract
 
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen
for HIV infection.
Mole L, Schmidgall D, Holodniy M. et al. 
J Acquir Immune Defic Syndr 2001 Jul1;27(3):260-5
Abstract

Indinavir/Zidovudine/Lamivudine
       
 
Efficacy, Safety, and Tolerability of Long-Term Combination Antiretroviral Therapy in
Asymptomatic Treatment-Naïve Adults with Early HIV Infection.
 McMahon DK, Dinubile MJ, Meibohm AR, et al 
HIV Clin Trials. 2007 Sep-Oct;8(5):269-81.
 Abstract
 
Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy
in HIV-Infected Adults: A Pilot Study.
 Anderson PL, Lamba J, Aquilante CL, 
J Acquir Immune Defic Syndr. 2006 Jun 19;
Abstract
 
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated
 patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
 Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, et al
Antivir Ther. 2006;11(2):223-32.
 Abstract

Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy
with indinavir, zidovudine, and lamivudine.
 Gulick RM, Meibohm A, Havlir D, et al 
AIDS. 2003 Nov 7;17(16):2345-2349.
 Abstract

FULL-TEXT ARTICLE
 The Triple Combination Indinavir-Zidovudine-Lamivudine Is Highly Synergistic. 
 Snyder S, D'Argenio DZ, Weislow O,  et al.
Antimicrob Agents Chemother 2000Apr;44(4):1051-1058
Paper
 
Predictors of Virologic and Clinical Outcomes in HIV-1-Infected Patients Receiving
Concurrent treatment with Indinavir, Zidovudine, and Lamivudine. AIDS Clinical Trials
Group Protocol 320.  
 Demeter LM, Hughes MD, Coombs RW, et al.
Ann Intern Med 2001  Dec 4;135(11):954-964
 Abstract
Misc. Regimens
       
 
Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir.
 Eiros Bouza JM, Ortega M, Ortiz de Lejarazu R ,et al
Int J Antimicrob Agents. 2004 Mar;23(3):304-6.
 Abstract

Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease
Inhibitor-Naive Adults with Advanced HIV Infection.
 Hirsch MS, Steigbigel RT, Staszewski S, et al
Clin Infect Dis. 2003 Oct 15;37(8):1119-24.
 Abstract
Drug Comparison Studies
       
 
Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast).
 Tanon AK, Eholié SP, Polneau S, et al
Med Mal Infect. 2008 Apr 3
Abstract

Journal Main Page Main New/Newsworthy  Home Page      

Indinavir Journal Adult/Adolescent Indications